CD Bioparticles Releases New Block Copolymer Micelles for Drug Delivery Research
As a leading manufacturer and supplier of various drug delivery products and services, CD Bioparticles launches a series of block copolymer micelles for global researchers to help solve the challenges faced in the studies such as limited drug-loading efficiency and yield, unpredictable or uncontrollable degradation rate of the drug-loading cargo, or uncontrollable drug delivery profile. These newly released products are applicable for a variety of potential usages, like biocompatible and biodegradable nanomaterials and bulk material fabrications, drug-delivery cargos with controllable delivery profile, and hydrogels with sol-gel transition useful for reversible encapsulation and delivery.
Many new products are released in the block copolymer micelles portfolio, such as Triblock Copolymers, which are vinylically reactive for binding into radical chain synthesized polymers, and AB Diblock Copolymers. For the latter products, the Acrylate-polycaprolactone-b-poly(ethylene glycol)-alkyne, for instance, is a biofunctional amphiphilic block copolymer with alkyne group at the end of PEG and acrylate at the end of polycaprolactone. ACRL-PCL-PEG-Alkyne is used to prepare micelles or nanoparticles with alkyne on the micelle surface for bioconjugation via click chemistry and acrylate in the micelle core for crosslinking. Hydrophobic drugs is encapsulated in the PCL core for targeted drug delivery.
Researchers now are accessible to a series of block copolymer for functional micelles fabrications, and gain lots of benefits such as degradable block copolymer with controllable degradation rate for sustainable release, controllable nanostructure for the assembly, cationic copolymers useful for gene delivery, bock copolymer assembled nanoparticles with controllable size and controllable core-shell ratio, and end-group functionalized block copolymers, useful for crosslinking and conjugation.
“When you’re lack of cell-specific or tissue-specific targeting for nanomedicines, or functional groups for further modification/conjugation/crosslinking, or you want to get rid of tedious chemical synthesis and purification, CD Bioparticles will be a good choice for you,” said Dr. Robin J. Watts, the product portfolio manager of CD Bioparticles. “CD Bioparticles is committed to developing quality drug delivery products and fulfilling our global clients’ needs, and these block copolymer micelles are added to our product portfolio of biopolymers & synthetic polymers, aiming to provide our customers more selection and value for reliable outcome.”
For more detailed information on block copolymer micelles or biopolymers & synthetic polymers, please contact CD Bioparticles directly.
About CD Bioparticles
CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems. It specializes in a range of formulation and drug delivery technologies, from conventional liposomes, PEGylated liposomes for drug delivery to polymer microspheres and nanoparticles for enhanced drug delivery. It provides contract services of drug delivery formulation developments for basic research, formulation feasibility studies, process development and scale-up, formulation characterization, analytical and nonclinical services.